Ras-mutated Metastatic Colorectal Cancer; mCRC; MSS Metastatic Colorectal Cancer
—
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Adlai Nortye Biopharma: exclusive development/commercialization rights in China, Hong Kong, Macau, Singapore, South Korea, Taiwan. PanCAN: Therapeutic Accelerator Award (up to $5M) funding a pelareorep pancreatic cancer trial. National Research Council of Canada: manufacturing collaboration.
2L+ squamous cell carcinoma of the anal canal(Phase 2)
Metastatic pancreatic ductal adenocarcinoma(Stage not disclosed)
Catalysts
— 2026 (fall/winter)
Status note Lead and only clinical asset. REO 033 randomized Phase 2 in 2L RAS-mutant MSS mCRC launched Mar 2026 (first site early Apr 2026); FDA Fast Track granted Q1 2026. GOBLET Cohort 4 in relapsed unresectable SCAC completed enrollment; Type C FDA meeting (Apr 2026) held on pivotal 2L+ SCAC trial; FDA Fast Track granted Jul 2026. Evaluating strategic options for registrational mPDAC program.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Breast Carcinoma; Metastatic Triple-Negative Breast Carcinoma
—
Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.